Lipoprotein associated phospholipase A2 inhibition reduces generation of oxidized fatty acids: Lp-LPA2 reduces oxidized fatty acids

Cardiovascular Drugs and Therapy

Volumn 22, Issue 1, 2008, Pages 55-58

  Rosenson, Robert S ^a   Vracar Grabar, Marina ^b   Helenowski, Irene ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Inflammation; Lipoprotein associated phospholipase A2; Lipoproteins; Oxidative stress

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 9 HYDROXYFATTY ACID; ESTERASE INHIBITOR; FATTY ACID; HYDROXY FATTY ACID; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; SB 677116; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FEMALE; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MALE; METABOLIC SYNDROME X; OXIDATION REDUCTION REACTION; PARTICLE SIZE; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATION-REDUCTION; PILOT PROJECTS;

EID: 39149145143     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-008-6080-4     Document Type: Article

References (14)

1. Rosenson RS, Koch AE. Inflammation, inflammatory disease, and atherosclerosis. In: Packard CJ, editor. The Year in Lipid Disorders. vol 13. London: Clinical Publishing; 2007. p. 273-93.
2. Koenig W, Khuseyinova N. Atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15-26.
3. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease & ischemic stroke: the Rotterdam study. Circulation 2005;111:570-5.
4. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-31.
5. Elinder LS, Dumitrescu A, Larsson P, Hedin U, Frostegard J, Claesson HE. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 1997;17:2257-63.
6. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Bio 1999;19:2909-17.
7. Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999;338:479-87.
8. Carpenter KL, Dennis IF, Challis IR, et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages. FEBS Lett, 2001;505:357-63.
9. Shi Y, Zhang P, Zhang L, et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 2007;191:54-62.
10. Kolodgie FD, Burke AP, Skorija K, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Bio 2006;26:2523-9.
11. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-70.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
13. Kaikkonen J, Tuomainen TP, Nyyssonen K, Morrow JD, Salonen JT. C18 hydroxy fatty acids as markers of lipid peroxidation ex vivo and in vivo. Scand J Clin Lab Invest 2004;64:457-68.
14. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-9.